TY - JOUR
T1 - Precision cancer medicine
T2 - Concepts, current practice, and future developments
AU - Edsjö, Anders
AU - Holmquist, Louise
AU - Geoerger, Birgit
AU - Nowak, Frédérique
AU - Gomon, Georgy
AU - Alix-Panabières, Catherine
AU - Ploeger, Carolin
AU - Lassen, Ulrik
AU - Le Tourneau, Christophe
AU - Lehtiö, Janne
AU - Ott, Patrick A.
AU - von Deimling, Andreas
AU - Fröhling, Stefan
AU - Voest, Emile
AU - Klauschen, Frederick
AU - Dienstmann, Rodrigo
AU - Alshibany, Aisha
AU - Siu, Lillian L.
AU - Stenzinger, Albrecht
PY - 2023
Y1 - 2023
N2 - Precision cancer medicine is a multidisciplinary team effort that requires involvement and commitment of many stakeholders including the society at large. Building on the success of significant advances in precision therapy for oncological patients over the last two decades, future developments will be significantly shaped by improvements in scalable molecular diagnostics in which increasingly complex multilayered datasets require transformation into clinically useful information guiding patient management at fast turnaround times. Adaptive profiling strategies involving tissue- and liquid-based testing that account for the immense plasticity of cancer during the patient's journey and also include early detection approaches are already finding their way into clinical routine and will become paramount. A second major driver is the development of smart clinical trials and trial concepts which, complemented by real-world evidence, rapidly broaden the spectrum of therapeutic options. Tight coordination with regulatory agencies and health technology assessment bodies is crucial in this context. Multicentric networks operating nationally and internationally are key in implementing precision oncology in clinical practice and support developing and improving the ecosystem and framework needed to turn invocation into benefits for patients. The review provides an overview of the diagnostic tools, innovative clinical studies, and collaborative efforts needed to realize precision cancer medicine.
AB - Precision cancer medicine is a multidisciplinary team effort that requires involvement and commitment of many stakeholders including the society at large. Building on the success of significant advances in precision therapy for oncological patients over the last two decades, future developments will be significantly shaped by improvements in scalable molecular diagnostics in which increasingly complex multilayered datasets require transformation into clinically useful information guiding patient management at fast turnaround times. Adaptive profiling strategies involving tissue- and liquid-based testing that account for the immense plasticity of cancer during the patient's journey and also include early detection approaches are already finding their way into clinical routine and will become paramount. A second major driver is the development of smart clinical trials and trial concepts which, complemented by real-world evidence, rapidly broaden the spectrum of therapeutic options. Tight coordination with regulatory agencies and health technology assessment bodies is crucial in this context. Multicentric networks operating nationally and internationally are key in implementing precision oncology in clinical practice and support developing and improving the ecosystem and framework needed to turn invocation into benefits for patients. The review provides an overview of the diagnostic tools, innovative clinical studies, and collaborative efforts needed to realize precision cancer medicine.
KW - clinical trials
KW - molecular diagnostics
KW - personalized oncology
KW - precision cancer medicine
KW - precision medicine networks
U2 - 10.1111/joim.13709
DO - 10.1111/joim.13709
M3 - Review article
C2 - 37641393
AN - SCOPUS:85169046024
SN - 0954-6820
VL - 294
SP - 455
EP - 481
JO - Journal of Internal Medicine
JF - Journal of Internal Medicine
IS - 4
ER -